StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) stock

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$156.50−3.23 (-2.02%)

Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –

Alnylam Pharmaceuticals ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Alnylam Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2026 was $1.03B, up 221.8% year over year. For fiscal 2025 it was $557.24M. The highest annual figure on record is $557.24M in fiscal 2025.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025$557.24M–
FY2024Dec 31, 2024-$120.22M–
FY2023Dec 31, 2023-$228.12M–
FY2022Dec 31, 2022-$740.60M–
FY2021Dec 31, 2021-$661.09M–
FY2020Dec 31, 2020-$793.67M–
FY2019Dec 31, 2019-$922.26M–
FY2018Dec 31, 2018-$799.43M–
FY2017Dec 31, 2017-$488.19M–
FY2016Dec 31, 2016-$409.46M–
FY2015Dec 31, 2015-$276.96M–
FY2014Dec 31, 2014-$393.05M–
FY2013Dec 31, 2013-$82.71M–
FY2012Dec 31, 2012-$120.42M–
FY2011Dec 31, 2011-$49.69M–
FY2010Dec 31, 2010-$39.13M–
FY2009Dec 31, 2009-$42.12M–
FY2008Dec 31, 2008-$22.11M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$360.27M-5.6%
Q2 FY2026Jun 30, 2026$245.34M–
Q1 FY2026Mar 31, 2026$282.19M+768.8%
Q4 FY2025Dec 31, 2025$145.22M–
Q3 FY2025Sep 30, 2025$381.79M–
Q2 FY2025Jun 30, 2025-$2.26M-103.5%
Q1 FY2025Mar 31, 2025$32.48M–
Q4 FY2024Dec 31, 2024-$90.99M–
Q3 FY2024Sep 30, 2024-$62.92M-127.7%
Q2 FY2024Jun 30, 2024$63.62M–
Q1 FY2024Mar 31, 2024-$29.92M–
Q4 FY2023Dec 31, 2023-$102.92M–
Q3 FY2023Sep 30, 2023$227.20M–
Q2 FY2023Jun 30, 2023-$216.65M–
Q1 FY2023Mar 31, 2023-$135.74M–
Q4 FY2022Dec 31, 2022-$174.30M–
Q3 FY2022Sep 30, 2022-$247.44M–
Q2 FY2022Jun 30, 2022-$181.59M–
Q1 FY2022Mar 31, 2022-$137.27M–
Q4 FY2021Dec 31, 2021-$183.19M–
Q3 FY2021Sep 30, 2021-$169.89M–
Q2 FY2021Jun 30, 2021-$134.36M–
Q1 FY2021Mar 31, 2021-$173.65M–
Q4 FY2020Dec 31, 2020-$183.84M–
Q3 FY2020Sep 30, 2020-$216.63M–
Q2 FY2020Jun 30, 2020-$190.66M–
Q1 FY2020Mar 31, 2020-$202.55M–
Q4 FY2019Dec 31, 2019-$292.63M–
Q3 FY2019Sep 30, 2019-$212.26M–
Q2 FY2019Jun 30, 2019-$232.42M–
Q1 FY2019Mar 31, 2019-$184.95M–
Q4 FY2018Dec 31, 2018-$210.93M–
Q3 FY2018Sep 30, 2018-$254.15M–
Q2 FY2018Jun 30, 2018-$190.12M–
Q1 FY2018Mar 31, 2018-$144.23M–
Q4 FY2017Dec 31, 2017-$145.06M–
Q3 FY2017Sep 30, 2017-$122.21M–
Q2 FY2017Jun 30, 2017-$117.41M–
Q1 FY2017Mar 31, 2017-$103.51M–
Q4 FY2016Dec 31, 2016-$112.42M–

More Alnylam Pharmaceuticals figures

See a number that looks wrong?